Pemvidutide: A Literature Course in Six Modules

Pemvidutide has been described in the peer-reviewed literature as an investigational peptide that activates both the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor, and it was evaluated in a randomised, double-blind, placebo-controlled study in people with metabolic dysfunction-associated steatotic liver disease (MASLD) (PMID 39002641). This course walks through six modules: what the compound is, the mechanism as authors describe it, reported outcomes study by study, adverse events as published, pharmacokinetics where data exist, and regulatory status. Each module closes with the limits of the evidence. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or treatment decision.

Module 1: What pemvidutide is and how it has been studied

Definition and class

The trial literature identifies pemvidutide as a GLP-1/glucagon dual receptor agonist, placing it in the broader class of peptide incretin co-agonists rather than among single-target GLP-1 receptor agonists (PMID 39002641). A separate randomised controlled trial published in JHEP Reports likewise studied it as a dual-agonist candidate in MASLD over a 24-week treatment period (PMID 41113119).

Origin and forms used in research

Across the published programme, pemvidutide was administered as a once-weekly subcutaneous injection, with the MASLD study evaluating weekly dose levels of 1.2 mg, 1.8 mg and 2.4 mg against placebo (PMID 39002641). The 24-week MASLD trial reported in JHEP Reports also used weekly administration over 24 weeks in a randomised, controlled design (PMID 41113119).

How it has been studied

The published studies were human clinical trials rather than animal work: a randomised, double-blind, placebo-controlled study in MASLD (PMID 39002641), a 24-week randomised controlled trial in MASLD (PMID 41113119), and a multicentre, randomised, double-blind phase 2b trial (IMPACT) in metabolic dysfunction-associated steatohepatitis that reported 24-week results (PMID 41237796). A GRADE-assessed meta-analysis of randomised controlled trials then pooled the available MASH evidence (PMID 41879841).

Limits of the evidence in Module 1: the verified literature describes a compact, liver-focused clinical programme. It does not establish long-term use beyond the reported 24-week windows, does not cover populations outside those enrolled, and contains no head-to-head comparison against other incretin-based agents in the verified papers.

Module 2: Mechanism as described in the literature

The mechanistic framing used by the authors is contained in the descriptor itself: pemvidutide was studied as a dual agonist at the GLP-1 receptor and the glucagon receptor (PMID 39002641). In pharmacological terms reported in this field, GLP-1 receptor activity is associated with effects on appetite signalling and gastric emptying, while glucagon receptor activity is associated with hepatic energy handling — and the rationale for combining the two in a liver-disease trial was that hepatic steatosis was the primary target of measurement (PMID 39002641).

The MASH phase 2b trial extended that rationale from fat content to histological disease activity, testing whether weekly treatment altered steatohepatitis endpoints relative to placebo at 24 weeks (PMID 41237796). The GRADE-assessed meta-analysis evaluated whether pooled randomised evidence supported efficacy and safety conclusions in MASH, and graded the certainty of that evidence (PMID 41879841).

What the mechanism sections do not claim

• The verified trials were clinical endpoint studies; they were not receptor-binding or signalling experiments, so relative receptor potency is not described in them.
• No verified paper mapped tissue distribution of receptor activation in humans.
• Mechanistic plausibility in these reports was inferred from measured endpoints, not from direct molecular readouts.

Limits of the evidence in Module 2: mechanism here is a description of drug class and study rationale, not a demonstrated causal pathway. Readers should treat statements about how dual agonism works as background pharmacology rather than as findings proved by the cited trials.

Module 3: Reported outcomes by study

Randomised placebo-controlled MASLD study

The Journal of Hepatology report described a randomised, double-blind, placebo-controlled study in participants with MASLD in which weekly pemvidutide at 1.2 mg, 1.8 mg and 2.4 mg was compared with placebo, with liver fat content as the focus of the primary analysis (PMID 39002641). Researchers reported reductions in liver fat content in the pemvidutide groups relative to placebo, alongside assessment of body weight and tolerability (PMID 39002641).

Twenty-four-week randomised controlled MASLD trial

A separate randomised, controlled clinical trial evaluated 24 weeks of pemvidutide in MASLD and reported both safety and efficacy outcomes across that treatment period (PMID 41113119). That report extended observation beyond the shorter liver-fat assessment windows used earlier in the programme, keeping placebo control in place for the full 24 weeks (PMID 41113119).

IMPACT phase 2b trial in MASH

IMPACT was described as a multicentre, randomised, double-blind phase 2b study of weekly pemvidutide versus placebo in metabolic dysfunction-associated steatohepatitis, with 24-week results published in The Lancet (PMID 41237796). The study reported safety and efficacy at week 24 in a biopsy-defined steatohepatitis population, which is a different and more demanding endpoint framework than imaging-based liver fat measurement (PMID 41237796).

GRADE-assessed meta-analysis

The 2026 meta-analysis pooled randomised controlled trials of pemvidutide in metabolic dysfunction-associated steatohepatitis and applied GRADE methodology to rate certainty for efficacy and safety outcomes (PMID 41879841). Pooled analyses of this kind summarise direction and consistency of effect across trials; they do not create new data, and their conclusions are bounded by the size and quality of the included studies (PMID 41879841).

Limits of the evidence in Module 3: these are phase 1b/2b-stage and pooled analyses at 24 weeks. No verified paper reported phase 3 outcome data, clinical event endpoints such as cirrhosis progression or mortality, or durability after treatment stopped. Nothing here should be read as a promise of benefit for any individual.

Module 4: Pemvidutide Side Effects: What Studies Report

Safety reporting appears in every verified publication. The randomised MASLD study assessed tolerability alongside its liver-fat endpoints and reported adverse events by dose group against placebo (PMID 39002641), and the 24-week randomised controlled trial in MASLD was explicitly framed as a safety-and-efficacy report (PMID 41113119).

Gastrointestinal events

As in other studies of incretin-based peptides, gastrointestinal adverse events such as nausea and vomiting were the adverse-event category most prominently reported in the MASLD trials, and researchers described them predominantly as mild to moderate in severity (PMID 39002641) (PMID 41113119). The phase 2b MASH trial similarly reported safety outcomes over 24 weeks of weekly dosing versus placebo (PMID 41237796).

Pooled safety assessment

The GRADE-assessed meta-analysis evaluated safety as well as efficacy across randomised trials in steatohepatitis, and rated the certainty of the pooled safety estimates rather than presenting them as definitive (PMID 41879841). Pooled adverse-event data from a small number of mid-stage trials typically carry wide confidence intervals for uncommon events, which is one reason GRADE ratings matter in interpreting such summaries (PMID 41879841).

Discontinuation and dose relationships

Because the MASLD study compared multiple weekly dose levels up to 2.4 mg against placebo, its adverse-event tables allowed examination of whether tolerability differed across dose groups (PMID 39002641), and the 24-week trial reported treatment discontinuations within its safety analysis (PMID 41113119).

Limits of the evidence in Module 4: trial safety data reflect screened participants monitored under protocol for 24 weeks. Rare events, long-term risks, interactions with other medicines and outcomes in people excluded from the trials were not characterised in the verified papers. Reported adverse-event frequencies cannot be transferred to unsupervised use.

Module 5: Pharmacokinetics where data exist

None of the four verified publications was a dedicated pharmacokinetic study; all were efficacy-and-safety reports or a pooled analysis of such reports (PMID 39002641) (PMID 41879841). What can be stated factually is the administration schedule the trials used: weekly subcutaneous dosing was the regimen tested in the MASLD study across 1.2 mg, 1.8 mg and 2.4 mg dose levels (PMID 39002641), and weekly administration was again used in the phase 2b MASH trial over 24 weeks (PMID 41237796).

A once-weekly schedule in late-phase trials generally implies a pharmacokinetic profile designed for extended exposure, but the verified reports did not publish half-life, clearance, volume of distribution, absorption rate or metabolite data within their stated scope (PMID 41113119). Readers looking for those parameters would need primary pharmacokinetic publications that are outside this verified set.

Limits of the evidence in Module 5: dosing interval is the only pharmacokinetic-adjacent fact these papers support. No exposure-response modelling, renal or hepatic impairment adjustment data, drug-interaction studies, or immunogenicity pharmacokinetics can be cited from the verified literature.

Module 6: Regulatory status, stated factually

In every verified publication, pemvidutide was studied as an investigational agent under randomised clinical trial protocols with placebo controls and institutional oversight (PMID 41237796) (PMID 39002641). Phase 2b reporting, by definition, describes a stage of development that precedes any marketing authorisation, and the verified papers do not describe pemvidutide as an approved medicine in any jurisdiction (PMID 41237796).

Approved products

There is no approved pemvidutide product described in the verified literature. Where an agent is investigational, its lawful human use occurs within an authorised clinical trial, and the trials in this set were conducted as multicentre randomised studies with defined protocols (PMID 41237796).

Research-use-only material

Peptide material sold for laboratory purposes is typically labelled "research use only" (RUO). RUO labelling means the material has not been evaluated or authorised for human administration and is intended for in vitro or laboratory research; it is a different legal category from a prescription medicine or an approved drug product.

Compounding

In the United States, pharmacy compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act is generally limited to bulk drug substances that are components of an FDA-approved drug, that appear in an applicable USP monograph, or that are included on FDA's relevant bulk drug substance lists. An investigational peptide that is not an approved active ingredient and is not on those lists does not meet those statutory criteria. This is general regulatory information and not legal advice.

Limits of the evidence in Module 6: regulatory categories change over time and vary by country. The verified papers document clinical-trial status only; they do not describe filings, approvals, or national scheduling decisions, and nothing here should be read as a statement about current law in a particular jurisdiction.

What the studies did not test

Reading the four verified publications together, several gaps are explicit:

• Beyond 24 weeks. The MASLD and MASH trials reported outcomes at 24 weeks, so longer-term efficacy and safety were not characterised (PMID 41113119) (PMID 41237796).
• Hard clinical outcomes. The verified studies used liver fat, histological and safety endpoints rather than events such as decompensation, transplantation or death (PMID 39002641).
• Populations outside the trials. Children, pregnancy, advanced cirrhosis and other excluded groups were not studied in the verified reports.
• Comparative effectiveness. No verified paper compared pemvidutide head-to-head with another approved incretin agent; the pooled analysis compared trial arms against placebo-controlled data (PMID 41879841).
• Non-trial use. Nothing in this literature examined self-directed use, research-use-only material, or administration outside protocol supervision.

The honest summary is that pemvidutide has a small but methodologically serious mid-stage evidence base in fatty liver disease, with safety signals dominated by gastrointestinal tolerability and certainty ratings that the meta-analysis authors themselves quantified (PMID 41879841). This page is educational and is not medical advice; questions about any therapy belong with a licensed physician.

References

• Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study (Journal of Hepatology, 2025)
• Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study (Lancet, 2025)
• Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial (JHEP Reports, 2025)
• Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials (Naunyn-Schmiedeberg's Archives of Pharmacology, 2026)